# A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

> **NCT05999799** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 161 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** GSK1070806
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05999799
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-16
- **Primary completion:** 2025-07-23
- **Final completion:** 2025-07-23
- **Target enrollment:** 161 (ACTUAL)
- **Why stopped:** Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified.
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05999799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05999799, "A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05999799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*